Listed

Eledon Pharmaceuticals, Inc.: Form 10-Q for the period ended Mar 31, 2019

Filed with the SEC on May 14, 2019 and accepted by EDGAR at May 14, 2019, 16:06 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2019-01-01 to 2019-03-31$3.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2019-01-01 to 2019-03-31−$4.9mus-gaap:OperatingIncomeLoss
Net income3 months2019-01-01 to 2019-03-31−$4.9mus-gaap:NetIncomeLoss
Diluted EPS3 months2019-01-01 to 2019-03-31−$0.52us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow3 months2019-01-01 to 2019-03-31−$4.0mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2019-03-31$9.1mus-gaap:Cash
Current assetsAt period end2019-03-31$10.3mus-gaap:AssetsCurrent
Total assetsAt period end2019-03-31$13.5mus-gaap:Assets
Current liabilitiesAt period end2019-03-31$3.2mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-03-31$3.5mus-gaap:Liabilities
Shareholders' equityAt period end2019-03-31$9.9mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-19-019134. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.